Reshma Kewalramani
At a glance: Reshma Kewalramani is CEO, President at Vertex Pharmaceuticals (VRTX). Their latest SEC Form 4, filed Nov 10, 2026, reported a sale of $6.3M. On file: 0 purchase lines ($0) and 14 sale lines ($26.0M).
Disclosed holdings: about $44.5M of VRTX stock: 86,471 shares reported on their latest Form 4 (filed Nov 10, 2026), valued at the Nov 20, 2026 close of $515.02. This counts only VRTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
CEO, President at Vertex Pharmaceuticals Inc / Ma (VRTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reshma Kewalramani's InsiderPrint
16 trades from SEC Form 4 filings, 2021 to 2026, drawn as one fingerprint.
Reading this print: Mostly sells, trading about 3 times a year, typically $1.2M a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.
- Bump outward: a purchase (2)
- Dent inward: a sale (14)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Stephane BancelCEO · MRNA · 94% match
- Trevor R. BurgessCEO · NP · 93% match
- William C. CobbCEO · FTDR · 90% match
- Clarence L. GrangerDirector · UCTT · 89% match
- Eric M. SprinkCEO · CCB · 89% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 10SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 11,86686,471 held (−12%) | $531.53 | $6.3M | -3.1% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 400137,878 held (−0%) | $479.75 | $192K | +7.4% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 120137,758 held (−0%) | $481.50 | $58K | +7.0% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 240137,518 held (−0%) | $482.84 | $116K | +6.7% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,510135,008 held (−2%) | $487.13 | $1.2M | +5.7% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 3,278131,730 held (−2%) | $488.27 | $1.6M | +5.5% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 460131,270 held (−0%) | $489.32 | $225K | +5.3% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,725128,545 held (−2%) | $490.54 | $1.3M | +5.0% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 949127,596 held (−1%) | $491.30 | $466K | +4.8% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,520125,076 held (−2%) | $493.29 | $1.2M | +4.4% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 3,498121,578 held (−3%) | $494.33 | $1.7M | +4.2% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 15,580105,998 held (−13%) | $495.38 | $7.7M | +4.0% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 5,995100,003 held (−6%) | $496.16 | $3.0M | +3.8% |
| Mar 3SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 1,72598,278 held (−2%) | $496.95 | $857K | +3.6% |
- Sell
CEO, President Reshma Kewalramani sold $6.3M of VRTX at $531.53 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Reshma Kewalramani sold $192K of VRTX at $479.75 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Reshma Kewalramani sold $58K of VRTX at $481.50 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Reshma Kewalramani sold $116K of VRTX at $482.84 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Reshma Kewalramani sold $1.2M of VRTX at $487.13 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Reshma Kewalramani sold $1.6M of VRTX at $488.27 — pre-scheduled 10b5-1 plan sale.
Follow Reshma Kewalramani
Get one email when Reshma Kewalramani files a new purchase or sale. Free.
At most one email a day about Reshma Kewalramani, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.